Podcast
MSL Talk: Tom Caravela, Mark Freebery, Rachel Pater
Rethinking for Success: Top 10 Lessons for Embracing the MSL mindset through insights from Adam Grant’s “Think Again”
Summary
In this episode, Tom Caravela is joined by Jeff Vaughn to explore the themes of Adam Grant's "Think Again". The discussion delves into intellectual humility, the importance of unlearning, and effective information dissemination. Tom and Jeff emphasize the value of embracing discomfort in communication and finding a balance between certainty and uncertainty. They explore the concepts of givers, takers, and matchers, offering insights into avoiding giver burnout and fostering psychological safety. The conversation also touches on the differences between education and real-world application and the importance of diverse personality types in teams. The episode concludes with reflections on the expert negotiator role and closing remarks.
This weeks guest is Jeff Vaughan, Director, North America Field Medical Science at Inizio Engage discusses Rethinking for Success: Top 10 Lessons for Embracing the MSL mindset through insights from Adam Grant’s “Think Again”.
This episode is sponsored Inizio Engage, a commercialization and strategic engagement partner for the healthcare industry, delivering solutions to meet the needs of patients, providers, payers, and pharmaceutical companies to improve the treatment experience and outcomes. Inizio creates personalized, impactful experiences and delivers an average of 5 million engagements annually across all healthcare stakeholders.
Jeff shares…
👉 Who is Adam Grant and why is this an important book
👉 What are the main areas where MSLs can “rethink” their way to success
👉 How does the book help with KOL development and relationships
👉 How to use psychological safety and embracing uncertainty in your MSL role
👉 How to be an expert “negotiator” according to Adam Grant
Think Again, intellectual humility, unlearning, psychological safety, diverse personality types
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Mark Freebery, Rachel Pater
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret